To evaluate the feasibility of @entity12418 plus @entity900 (AP) following chemoradiotherapy for limited-disease @entity151 , chemo-na  ve @entity1 aged 20-70 years with a performance status of 0 or 1 and normal organ functions were treated with @entity2879 100 mg/m(2) on days 1-3, @entity900 80 mg/m(2) on day 1 and concurrent thoracic radiotherapy at 45 Gy/30 fractions (EP-TRT), followed by three cycles of @entity12418 40 mg/m(2) on days 1-3 and @entity900 60 mg/m(2) on day 1 every 3 weeks. The EP-TRT could be completed in 21 @entity1 (15 male and 6 female @entity1 with a median age of 62 years). Of these, 2, 1 and 18 (86%) @entity1 received one, two and three cycles of AP, respectively. Sixteen (76%) @entity1 required @entity1261 ( @entity1261 ) support. Grade 3/4 @entity1398 occurred in all @entity1 . Grade 3 @entity1398 was observed in 9 @entity1 , lasting for 1 day in 5 @entity1 . The incidences of grade 3/4 @entity882 and @entity417 were 43 and 24%, respectively. Grade 3 @entity281 and @entity448 occurred in 2 and 3 @entity1 , respectively. The response rate was 95%. The median (95% confidence interval [CI]) progression-free survival (PFS) was 41.9 (0-102) months, and the 5-year PFS rate (CI) was 41.9% (20.4-63.4%). The median overall survival (OS) has not been reached yet, and the 5-year OS rate (CI) was 57.8% (35.2-80.4%). In conclusion, EP-TRT followed by AP therapy was well-tolerated, although a large number of @entity1 required @entity1261 support.

Feasibility study of chemoradiotherapy followed by @entity12418 and @entity900 for limited-disease XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity12418 :: ('MESH:C055866', 'Chemical') :: ['amrubicin'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity151 :: ('MESH:D055752', 'Disease') :: ['small-cell lung cancer']
@entity151 :: (MESH:D055752,Disease) :: ['small cell lung cancer']
